T. Rowe Price Investment Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,139,254 shares of ALNY stock, worth $770 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
3,139,254
Previous 3,153,627
0.46%
Holding current value
$770 Million
Previous $766 Million
12.67%
% of portfolio
0.52%
Previous 0.48%
Shares
9 transactions
Others Institutions Holding ALNY
# of Institutions
643Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$4.05 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.1 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.34 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.29 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.22 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.2B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...